2 results
Approved WMORecruiting
To assesses the efficacy of Tinlarebant in slowing the rate of growth of atrophic lesion(s) in adolescent subjects with STGD1.
Approved WMOPending
Main objective: To evaluate the efficacy of BIIB122 225 mg compared with placebo.Secondary objective: To evaluate the efficacy, safety and tolerability of BIIB122 225 mg compared with placebo in participants with early-stage PDObjective optional (…